GHK-Cu and the ambition for firmer skin

Collagen in a culture dish

In human fibroblast cultures studied in 1988, GHK-Cu increased collagen synthesis without changing cell number. The response began between 10^-12 and 10^-11 M and reached its maximum at 10^-9 M. These were concentrations in culture medium. The cells were making more collagen, with no accompanying increase in their number.

I admire the fibroblast experiment for separating collagen output from cell number. Fibroblasts make supporting material; the investigators measured a change in that work. A whole-person claim about defying age would need a very different experiment.

GHK, copper and ageing blood

GHK is a chain of three amino acids: glycine, histidine and lysine. GHK-Cu is the copper-bound complex. The GHK sequence occurs in human plasma and in the type-I form of collagen; a 2015 review describes plasma levels falling from about 200 ng/mL at age 20 to about 80 ng/mL by age 60.

I distrust replacement targets inferred from an age comparison alone. It documents a difference in circulating GHK. It does not establish a human replacement target or show that raising the level reverses ageing.

The tissue-remodelling literature describes collagen, elastin and repair signals, with copper contributing to the enzymes involved in cross-linking structural proteins. The free peptide and its copper complex need to be distinguished when following those findings.

Topical trials and penetration

A 2025 review of topical GHK reports increased procollagen synthesis in 70% of treated subjects, versus 50% for vitamin C and 40% for retinoic acid. The same review describes poor passage through the outer skin layer and experimental efforts to improve delivery, including modified peptides and microneedle pretreatment. Those delivery experiments describe research procedures, not a home-use routine.

The older skin-layer experiment measured copper from GHK-Cu in excised human skin. Over 48 hours, 136.2 ± 17.5 micrograms/cm² permeated dermatomed skin and 97 ± 6.6 micrograms/cm² remained as a dermal depot. These measurements concern copper in a particular preparation of skin outside the body. They cannot tell us how much intact GHK-Cu a face cream delivers in everyday use.

I assign much of the credit or blame to the formulation. A substance placed directly in culture medium and a substance spread on intact skin face quite different journeys. I expect the barrier and the carrier to influence the outcome.

The hair trial had another ingredient

A 6-month randomised trial in 45 men with androgenetic hair loss tested GHK combined with 5-aminolevulinic acid. Hair-count increases were 52.6 in the 100 mg/mL group and 71.5 in the 50 mg/mL group, compared with 9.6 for placebo; the reported difference was statistically significant (p<0.05). No adverse events were reported in any group.

The concentrations describe the combination tested in that study. Its result supports further interest in that preparation. The experiment leaves the contribution of GHK alone unresolved, and it tested a different material from pure GHK-Cu.

Skin tolerability and systemic unknowns

People discussing copper-peptide skincare describe firmer-feeling skin, hydration, smoother texture and less hair shedding. Others describe redness, dryness, itching, breakouts or a duller appearance nicknamed the copper uglies. These are anecdotal accounts rather than clinical evidence. Pigment reports run in both directions: some describe more even tone, others darker spots. None of those accounts establishes a reliable chance of benefit or harm.

The topical review describes a substantial delivery and formulation problem. Low-pH acids and strong reducing agents such as ascorbic acid can destabilise the copper complex; irritation and compatibility are part of the topical discussion. Systemic copper accumulation is a theoretical concern, especially with copper-handling disorders such as Wilson's disease. Published human copper-toxicity cases attributed to GHK-Cu have not been established in this record.

Topical Copper Tripeptide-1 has a long cosmetic history. Injectable GHK-Cu has no validated human pharmacokinetic basis: the missing information includes exposure, distribution and clearance. GHK-Cu has no FDA-approved drug indication. The cream findings sustain my interest. The injection claims remain unanswered.

ACCESS AND EVIDENCE

Clinical review does not widen the GHK-Cu record

Community injection accounts do not establish GHK-Cu clinically; Promise Peptides, whose web address is mypromise.com, now prescribes compounded injectable GHK-Cu under its licensed U.S. clinician's case-by-case judgement. Its clinician may refuse a prescription, and the compounded product has no FDA approval; clinical oversight leaves this page's evidence limits intact.

The much larger gene claim

The 2018 review of gene-expression findings describes GHK-associated changes in repair, antioxidant and DNA-repair gene sets, drawing heavily on database analysis. At a 50%-or-greater expression-change threshold, the defensible tally is on the order of 2,100 genes. The familiar claim of about 4,000 genes uses a broader extrapolation.

Gene expression measures activity in a biological system. It leaves substantial work between a signal in the data and a durable benefit in people. Much of this broader literature comes from a small group of authors. A longer list of pathways excites me less than replication and measured human outcomes.